SCHEMBL2468459

SCHEMBL2468459

Cc1cccc(CCNC(=O)C2(c3ccccc3)CCN(C(=O)CCc3ccc(F)cc3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.50
CHRM3 P20309 1/20 0.50
GFER P55789 1/20 0.47
EPHX2 P34913 1/20 0.46
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44
PLAAT2 Q9NWW9 1/20 0.44
PLAAT4 Q9UL19 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
OPRL1 P41146 2/20 0.44
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
GPR183 P32249 1/20 0.43
USP7 Q93009 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2467231 0.92 OPRL1 (0.51) GFEREPHX2OPRL1OPRM1GPR183
SCHEMBL2471846 0.92 CHRM5 (0.50) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2468618 0.92 CHRM5 (0.54) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2492390 0.90 CHRM5 (0.51) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2469451 0.89 PLAAT3 (0.49) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2517627 0.88 CHRM5 (0.54) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2470510 0.88 CHRM5 (0.46) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2469740 0.88 TACR1 (0.48) CHRM5CHRM3GFEREPHX2PLAAT3
SCHEMBL2468267 0.87 METAP2 (0.52) CHRM5CHRM3OPRL1OPRM1OPRD1
SCHEMBL13688315 0.86 CHRM5 (0.60) CHRM5CHRM3GFEREPHX2OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 CHRM5 676/4885CHRM3 1015/4885GFER 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.